ES2061736T3 - Anticuerpos monoclonales contra interleucina-4 humana e hibridomas que los producen. - Google Patents

Anticuerpos monoclonales contra interleucina-4 humana e hibridomas que los producen.

Info

Publication number
ES2061736T3
ES2061736T3 ES88910302T ES88910302T ES2061736T3 ES 2061736 T3 ES2061736 T3 ES 2061736T3 ES 88910302 T ES88910302 T ES 88910302T ES 88910302 T ES88910302 T ES 88910302T ES 2061736 T3 ES2061736 T3 ES 2061736T3
Authority
ES
Spain
Prior art keywords
chain variable
variable region
monoclonal antibodies
human
hybridomes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88910302T
Other languages
English (en)
Inventor
John S Abrams
Isabelle Chretien
Frank D Lee
Michael K Pearce
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Schering Biotech Corp
Original Assignee
Schering Biotech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Biotech Corp filed Critical Schering Biotech Corp
Application granted granted Critical
Publication of ES2061736T3 publication Critical patent/ES2061736T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Un método para producir un anticuerpo monoclonal específico para la interleucina-4 humana, o un polipéptido que comprende una región variable de cadena ligera o una región variable de cadena pesada del mismo, o una composición para unión específica para la interleucina-4 humana que comprende una región variable de cadena pesada y una región variable de cadena ligera de la misma, que comprende (a) cultivar un hibridoma elegido entre los hibridomas IC1.11B4.6 y MP4.25D2.11 (ATTC HB 9550 y HB 8909) o (b) producir dichos anticuerpos monoclonales, polipéptidos o composiciones para unión mediante sistemas recombinantes, y, si se desea, generar fragmentos a partir de los productos producidos o llevar a cabola reasociación química de hemimoléculas.
ES88910302T 1987-10-26 1988-10-21 Anticuerpos monoclonales contra interleucina-4 humana e hibridomas que los producen. Expired - Lifetime ES2061736T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/113,623 US5041381A (en) 1986-07-03 1987-10-26 Monoclonal antibodies against human interleukin-4 and hybridomas producing the same

Publications (1)

Publication Number Publication Date
ES2061736T3 true ES2061736T3 (es) 1994-12-16

Family

ID=22350540

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88910302T Expired - Lifetime ES2061736T3 (es) 1987-10-26 1988-10-21 Anticuerpos monoclonales contra interleucina-4 humana e hibridomas que los producen.

Country Status (18)

Country Link
US (1) US5041381A (es)
EP (2) EP0314402A3 (es)
JP (1) JPH0698020B2 (es)
KR (1) KR930008112B1 (es)
CN (2) CN1032816A (es)
AU (1) AU611750B2 (es)
CA (1) CA1335653C (es)
DE (1) DE3886760T2 (es)
DK (1) DK169627B1 (es)
ES (1) ES2061736T3 (es)
HK (1) HK105996A (es)
IE (1) IE62491B1 (es)
IL (1) IL88145A0 (es)
MY (1) MY108526A (es)
NZ (1) NZ226692A (es)
PT (1) PT88847B (es)
WO (1) WO1989003846A2 (es)
ZA (1) ZA887987B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5700915A (en) * 1985-11-19 1997-12-23 Schering Corporations Human interleukin immunopurification processes
EP0327283B1 (en) * 1988-02-02 1993-08-18 Schering Biotech Corporation Method of reducing immunoglobulin e responses
WO1991008774A1 (en) * 1989-12-15 1991-06-27 Cetus Corporation Cytokine antibody for the treatment of sepsis
GB8928501D0 (en) * 1989-12-18 1990-02-21 Unilever Plc Reagents
WO1991009059A1 (en) * 1989-12-20 1991-06-27 Schering Corporation Antibody antagonists of human interleukin-4
US5132109A (en) * 1990-10-05 1992-07-21 Ludwig Institute For Cancer Research Method for inhibiting production of ige and method for enhancing production of igg using interleukin 9 and inhibitors thereof
DE4137333A1 (de) * 1991-11-13 1993-05-19 W Prof Dr Sebald Therapeutische mittel, die antagonisten oder partielle agonisten des humanen interleukin 4 sind oder diese enthalten, hil-4-mutantenproteine sowie vefahren zu deren herstellung
US5863537A (en) * 1992-02-19 1999-01-26 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US5714146A (en) * 1992-08-26 1998-02-03 Board Of Regents Of The University Of Washington IL-4 bone therapy
US20020193575A1 (en) * 1993-09-07 2002-12-19 Smithkline Beecham P.L.C. Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US5914110A (en) * 1993-09-07 1999-06-22 Smithkline Beecham Corporation Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
AP583A (en) * 1993-09-07 1997-04-14 Smithkline Beecham Corp Recombination IL4 antibodies useful in treatment of IL4 mediated disorders.
US5928904A (en) * 1993-09-07 1999-07-27 Smithkline Beecham Corporation DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US5959085A (en) * 1993-11-23 1999-09-28 Schering Corporation Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
EP0659766A1 (en) * 1993-11-23 1995-06-28 Schering-Plough Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
AU1744495A (en) * 1994-02-15 1995-08-29 T Cell Diagnostics, Inc. Immunoassay kit comprising universal reagents
US5597710A (en) * 1994-03-10 1997-01-28 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US5705154A (en) * 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
AUPN481295A0 (en) * 1995-08-16 1995-09-07 Medvet Science Pty. Ltd. Agonists of haemopoietic growth factors
US20020090682A1 (en) * 1995-10-23 2002-07-11 Tracy Willson Novel haemopoietin receptor and genetic sequences encoding same
PT2990420T (pt) 2000-05-26 2017-03-16 Immunex Corp Uso de anticorpos de recetor de interleucina-4 e composições dos mesmos
GB0210535D0 (en) * 2002-05-08 2002-06-19 Novartis Ag Organic compounds
JP2004045384A (ja) * 2002-05-22 2004-02-12 Matsushita Electric Ind Co Ltd 免疫学的測定方法、免疫学的測定装置、生体成分測定用トイレ、抗アルブミンモノクローナル抗体、それを産生する細胞株、およびアルブミン検出キット
US20070104710A1 (en) * 2002-06-28 2007-05-10 Domants Limited Ligand that has binding specificity for IL-4 and/or IL-13
US20110223168A1 (en) * 2002-12-27 2011-09-15 Greg Winter Ligand that has binding specificity for il-4 and/or il-13
AR050044A1 (es) * 2004-08-03 2006-09-20 Novartis Ag Anticuerpo especifico de il-4
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
GB0807214D0 (en) * 2008-04-21 2008-05-28 Belfast Health And Social Care Biomarkers
GB201210571D0 (en) * 2012-06-14 2012-08-01 Belfast Health And Social Care Trust Predictive biomarker
GB201210587D0 (en) * 2012-06-14 2012-08-01 Belfast Health And Social Care Trust Predictive biomarker
CN103421747B (zh) * 2013-09-09 2015-01-07 扬州大学 分泌牛il-4单克隆抗体的杂交瘤细胞株、其单克隆抗体及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4255329A (en) 1973-10-02 1981-03-10 Syva Company Double receptor fluorescent immunoassay
US4342832A (en) 1979-07-05 1982-08-03 Genentech, Inc. Method of constructing a replicable cloning vehicle having quasi-synthetic genes
US4431739A (en) * 1979-11-05 1984-02-14 Genentech, Inc. Transformant bacterial culture capable of expressing heterologous protein
US4423147A (en) 1980-04-11 1983-12-27 Secher David S Monoclonal antibody to interferon-α
DE3161585D1 (en) 1980-06-20 1984-01-12 Battelle Memorial Institute A method for the delignification of wood and other ligno-cellulosic products
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4355023A (en) 1980-09-30 1982-10-19 The Massachusetts General Hospital Antibody fragment compositions and process
US4599308A (en) 1981-10-06 1986-07-08 Hamer Dean H Protein from SV40 recombinants
US4470925A (en) 1982-05-05 1984-09-11 E. I. Du Pont De Nemours And Company Immunoglobulin half-molecules and process for producing hybrid antibodies
US4474493A (en) 1982-09-09 1984-10-02 Modular Systems, Inc. Dowel fastener and joints including same
AU566610B2 (en) 1983-09-15 1987-10-22 University Of Bath Disinfection of contact lenses
US4731237A (en) 1983-11-07 1988-03-15 The Wistar Institute Immune response to virus induced by anti-idiotype antibodies
WO1986000991A1 (en) 1984-07-24 1986-02-13 Commonwealth Serum Laboratories Commission Method for determining mimotopes
US4562003A (en) 1984-10-26 1985-12-31 California Biotechnology, Inc. Monoclonal antibodies against alveolar surfactant protein
EP0190711B1 (en) 1985-02-07 1989-04-26 Kowa Company, Ltd. Monoclonal antibodies to tissue plasminogen activator derived from human normal cells
WO1986006487A1 (en) 1985-04-22 1986-11-06 Commonwealth Serum Laboratories Commission Method for determining mimotopes
PT83761B (pt) * 1985-11-19 1989-06-30 Schering Biotech Corp Metodo para a producao de interleuquina-4 de mamifero

Also Published As

Publication number Publication date
DE3886760T2 (de) 1994-09-08
EP0375743B1 (en) 1993-12-29
HK105996A (en) 1996-06-28
DK101890D0 (da) 1990-04-25
IL88145A0 (en) 1989-06-30
WO1989003846A3 (en) 1989-05-18
EP0375743A1 (en) 1990-07-04
EP0314402A2 (en) 1989-05-03
NZ226692A (en) 1991-06-25
DK169627B1 (da) 1994-12-27
JPH0698020B2 (ja) 1994-12-07
KR930008112B1 (ko) 1993-08-26
US5041381A (en) 1991-08-20
PT88847B (pt) 1993-01-29
AU611750B2 (en) 1991-06-20
DE3886760D1 (de) 1994-02-10
CN1032816A (zh) 1989-05-10
IE62491B1 (en) 1995-02-08
WO1989003846A2 (en) 1989-05-05
AU2782789A (en) 1989-05-23
MY108526A (en) 1996-10-31
EP0314402A3 (en) 1989-06-07
DK101890A (da) 1990-04-25
KR890701632A (ko) 1989-12-21
CN1176391A (zh) 1998-03-18
IE883213L (en) 1989-04-26
CA1335653C (en) 1995-05-23
ZA887987B (en) 1990-06-27
JPH03503118A (ja) 1991-07-18

Similar Documents

Publication Publication Date Title
AU664801B2 (en) Humanised antibodies
IL124689A0 (en) Apoptosis induced by monoclonal antibody anti-her2
DK0380068T3 (da) Ekspressionssystem til fremstilling af kimære monoklonale antistoffer
IT8319234A0 (it) Procedimento per la produzione di anticorpi monoclonali umani.
RU96107203A (ru) Моноклональные антитела, обладающие способностью вызывать апоптоз
AU8567891A (en) Monoclonal antibody against melanoma
ES2114064T3 (es) Inmunoanalisis para la deteccion de colageno o fragmentos de colageno.
DK407987A (da) Apolipoprotein b-specifikke monoklonale antistoffer og hybridomer, som producerer disse antistoffer
ES2015654A6 (es) Un procedimiento para preparar anticuerpos anti-idiotipicos para antigeno asociado con melanoma, de alto peso molecular anti-humano.
DE68911713D1 (de) Monoklonale Antikörper, die atriales natriuretisches Polypeptide erkennen, ihre Herstellung und Verwendung.
EP0166458A3 (en) Monoclonal antibody capable of specifically distinguishing human hepato-carcinoma cells
EP0255367A3 (en) Cancer cell specific monoclonal antibodies and corresponding hybridomas, and their preparation and use
IT1254705B (it) Anticorpi monoclonali specifici per il fattore neuronotrofico ciliare (cntf) umano ricombinante
KR960701987A (ko) 단일클론 항체 88bv59, 서브클론 및 이들의 제조 방법(monoclonal antibody 88bv59, subclones and method of making)
BG51405A1 (en) Hybridome cellular line secreting monoclonal antibody ageinst human erythrocytec blood group antigen b

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 375743

Country of ref document: ES